By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Insider activity at Biocryst Pharmaceuticals Inc has been all selling for a year now: about $4.1 million from four sellers, and zero buyers on the open market.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. Members of Congress reported 2 trades in BCRX over the past two years (one member). Big money check: 318 institutions held BCRX as of Q2 2026, and more funds bought than sold.
Are insiders buying or selling BCRX stock?
In the last 12 months Biocryst Pharmaceuticals Inc insiders made open-market purchases worth about $0 and sales worth about $4.1 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in BCRX?
The most recent open-market insider trade in BCRX was filed on 2026-05-19.
How many institutions own BCRX?
318 investment managers reported holding BCRX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded BCRX?
Yes. Members of Congress reported 2 trades in BCRX over the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).